Regeneron Technology definition

Regeneron Technology means any invention, Know-how or other information, whether tangible or intangible, whether or not patentable in the Field, and which:

Regeneron Technology means the Regeneron Know-How and Regeneron Patent Rights including with respect to any Mice Invention.

Regeneron Technology means any invention, Know-how or other information, whether tangible or intangible, whether or not patentable in the Field, and which: (a) is not Regeneron Excluded Technology, and (b) is conceived or reduced to practice by Regeneron or acquired or licensed by Regeneron from a Third Party with the right to sublicense, (i) before or during the Research Term; or (ii) after the Research Term, but during the term of a J-V, regarding a Development Compound or Marketed Compound. Regeneron Technology may include, without limitation, research methods and materials (including without limitation genetic materials, receptors, cell lines and transgenic animals) useful in performing research, Targets, Compounds, formulations, chemical synthesis and manufacturing processes, methods of diagnosis and methods of treatment. 1.49. "Research Collaboration Plan" means, on a Fiscal Year basis, the compilation of objectives, prioritization of Research Projects and work on new areas of research, Success Criteria and overall budget for work by the Parties during the Research Term, but not including development and/or marketing activities. 1.50. "Research Compound" means a Compound that has not yet met the Success Criteria. 12 <PAGE> 1.51. "Research Project" shall mean research conducted by the Parties for the purpose of identifying, optimizing, and testing a specific Target, Validated Target and/or Research Compound. 1.52. "Research Project Plan" shall mean, on a Fiscal Year basis, the compilation of activities, milestones, budget, and Success Criteria relating to a Research Project. 1.53. "Research Term" means the period of time beginning on the Effective Date and unless terminated earlier pursuant to 10.3, ending December 31, 2005. 1.54. "Retained Projects" means the Mutual Retained Projects, Procter & Xxxxxx Retained Projects, and Regeneron Retained Projects. 1.55. "Royalty Term" means the period from the first Net Sales in the first country to the final payment of royalties in the last country pursuant to Section 6.1. 1.56. "Section" means any section of this Agreement. 1.57. "Securities Agreements" mean the following agreements between the parties: the Registration Rights Agreement, the Securities Purchase Agreement and the Warrant Agreement, all dated May 13, 1997, as each may be amended, supplemented or modified from time to time and the Stock Purchase Agreement and Registration Rights Agreement both dated December 11, 1996, as each may be amended, supplemented or modified ...

Examples of Regeneron Technology in a sentence

• Regeneron Technology may include, without limitation, research methods and materials (including without limitation genetic materials, receptors, cell lines and transgenic animals) useful in performing research, Targets, Compounds, formulations, chemical synthesis and manufacturing processes, methods of diagnosis and methods of treatment.

• In any press releases issued by Company regarding the discovery, development or approval of a Subject Product, Antibody or Antibody Materials, Company shall include a statement regarding the role of Regeneron Technology and Mice, which statement shall be reasonably acceptable to Regeneron.

• Other than the grant of license in Section 2.1, Regeneron retains all right, title and interest in and to the Regeneron Technology, Mice, and Mice Materials described in Exhibit A.

• The respective shares were 54 and 33.5% in the academic year 1998/1999.7 From the figures we have presented so far it follows that young women today in Greece outscore men in human capital investments at all levels of post­compulsory education, with the exception of doctoral studies.

• In the event that either Party or any of its Affiliates shall receive written notice from a Third Party claiming that the Mice, Mice Materials or Regeneron Technology infringes or otherwise violates the intellectual property rights of such Third Party, then such Party shall promptly notify the other Party in writing of this notice of infringement.

• In the event Regeneron and Company are unable to agree on such terms, then the subject matter of such intellectual property shall not be included within the definition of Regeneron Technology, and Company shall have no license or rights with respect to such intellectual property.

• As of the Effective Date, Regeneron has no Affiliates that Control any Regeneron Technology.

• This non-exclusive license does not include the right to have sold or sell Regeneron Technology, including, without limitation, Regeneron Compounds, under Regeneron Know-how and Regeneron Patents.

• Section 8.5 shall not apply to Regeneron Confidential Information during the term of this Agreement or on the expiry or termination of this Agreement if and to the extent that Company’s rights under the Regeneron Technology survive such termination or expiry pursuant to Section 9.4.

• If Regeneron acquires rights to additional intellectual property from a Third Party required by Company for its use of the Mice or Regeneron Technology under this Agreement that requires no payments to such Third Party and that permits Regeneron to include such intellectual property in the scope of the license grants in Section 2.1 of this Agreement, such intellectual property shall be included in this Agreement at no additional charge to Company.

More Definitions of Regeneron Technology

Regeneron Technology means the Regeneron Know-How and Regeneron Patent Rights including with respect to any Mice Invention. 1.29 “Royalty Term” shall have the meaning set forth in Section 4.3. 1.30 “SEC” shall mean the United States Securities and Exchange Commission. 1.31 “Site” shall mean ********************************* and any site of a Company’s Affiliate or Approved Third Party upon prior written notification of the address of such facility(ies) to Regeneron. 1.32 “Subject Product” shall mean any product (including, without limitation, any therapeutic or diagnostic for human or veterinary use) that contains as an ingredient or component an Antibody or Antibody Materials. 1.33 “Therapeutic Subject Products” shall mean all Subject Products except for Diagnostic Subject Products. 1.34 “Third Party” shall mean any Person other than Regeneron, Company, or their respective Affiliates. 1.35 “Transfer Date” shall mean the date upon which the first delivery of Mice from Regeneron are received by Company pursuant to Section 3.3 or ********************. 1.36 “US CPI” shall mean the Consumer Price Index —Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-1984 = 100, published by the United States Department of Labor, Bureau of Statistics (or its successor equivalent index) or such other index as may be mutually agreed upon by the Parties. 1.37 “Valid Claim” shall mean a claim which satisfies both of the conditions set forth in (i) and (ii) below: (i) the relevant claim is either (a) a claim of an issued and unexpired patent

Regeneron Technology means any invention, Know-how or other information, whether tangible or intangible, whether or not patentable in the Field, and which: (a) is not Regeneron Excluded Technology, and (b) is conceived or reduced to practice by Regeneron or acquired or licensed by Regeneron from a Third Party with the right to sublicense, (i) before or during the Research Term; or (ii) after the Research Term, but during the term of a J-V, regarding a Development Compound or Marketed Compound. Regeneron Technology may include, without limitation, research methods and materials (including without limitation genetic materials, receptors, cell lines and transgenic animals) useful in performing research, Targets, Compounds, formulations, chemical synthesis and manufacturing processes, methods of diagnosis and methods of treatment. 1.49. "Research Collaboration Plan" means, on a Fiscal Year basis, the compilation of objectives, prioritization of Research Projects and work on new areas of research, Success Criteria and overall budget for work by the Parties during the Research Term, but not including development and/or marketing activities. 1.50. "Research Compound" means a Compound that has not yet met the Success Criteria. 12 <PAGE> 1.51. "Research Project" shall mean research conducted by the Parties for the purpose of identifying, optimizing, and testing a specific Target, Validated Target and/or Research Compound. 1.52. "Research Project Plan" shall mean, on a Fiscal Year basis, the compilation of activities, milestones, budget, and Success Criteria relating to a Research Project. 1.53. "Research Term" means the period of time beginning on the Effective Date and unless terminated earlier pursuant to 10.3, ending December 31, 2005. 1.54. "Retained Projects" means the Mutual Retained Projects, Procter & Xxxxxx Retained Projects, and Regeneron Retained Projects. 1.55. "Royalty Term" means the period from the first Net Sales in the first country to the final payment of royalties in the last country pursuant to Section 6.1. 1.56. "Section" means any section of this Agreement. 1.57. "Securities Agreements" mean the following agreements between the parties: the Registration Rights Agreement, the Securities Purchase Agreement and the Warrant Agreement, all dated May 13, 1997, as each may be amended, supplemented or modified from time to time and the Stock Purchase Agreement and Registration Rights Agreement both dated December 11, 1996, as each may be amended, supplemented or modified ...